A combination of anti-erbb-2 monoclonal antibodies and method of using
CA 2120745 A1 · Owner: Oncologix, Inc. · Inventors: Kasprzyk, Philip G.; King, Charles R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a combination of at least two monolconal antibodies which are capable of preventing and treating human malignancies wherein the malignant cells overexpress gp185erbB-2. The monoclonal antibodies of the combination recognize different epitopes of the gp185 expression product of erbB-2 therefore, the antibodies do not cross react with each other. Preferably the combination decreases the expression product of the erbB-2 gene. In another embodiment, the combination does not essentially increase tyrosine phosphorylation of the gp185 expression product.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 21, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 21, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 21, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.